Signaling molecules involved in lipid-induced pancreatic beta-cell dysfunction

Area of Science:

• Endocrinology
• Molecular Biology
• Metabolic Diseases

Background:

• Rising obesity rates correlate with increased type 2 diabetes mellitus incidence.
• Elevated free fatty acids (FFAs) are implicated in beta-cell dysfunction and apoptosis, termed lipotoxicity.
• The molecular mechanisms underlying FFA-induced beta-cell dysfunction are complex and not fully elucidated.

Purpose of the Study:

• To review and synthesize current knowledge on molecular effectors involved in FFA-induced beta-cell dysfunction.
• To highlight newly identified factors contributing to the lipotoxicity pathway.
• To provide a comprehensive overview of the molecular network governing lipotoxicity.

Main Methods:

• Literature review of studies investigating FFA-induced beta-cell dysfunction.
• Identification and description of key signaling pathways and molecular players.
• Synthesis of information on factors such as SREBP-1c, FXR, FoxO1, UCHL1, NDRG2, perilipins, Sirt1, PACAP, and ghrelin.

Main Results:

• Several factors, including sterol regulatory element-binding protein (SREBP)-1c, farnesoid X receptor (FXR), and forkhead box-containing protein O (FoxO) 1, are involved in FFA-induced beta-cell dysfunction.
• Other critical effectors identified include ubiquitin C-terminal hydrolase L (UCHL) 1, N-myc downstream-regulated gene (NDRG) 2, perilipin family proteins, silent information regulator 2 protein 1 (Sirt1), pituitary adenylate cyclase-activating polypeptide (PACAP), and ghrelin.
• These factors collectively contribute to the complex molecular network underlying lipotoxicity.

Conclusions:

• Understanding the roles of SREBP-1c, FXR, FoxO1, UCHL1, NDRG2, perilipins, Sirt1, PACAP, and ghrelin is crucial for comprehending FFA-induced beta-cell dysfunction.
• This review provides insights into the molecular blueprint of lipotoxicity, aiding further research into type 2 diabetes.
• Further investigation into these effectors may reveal novel therapeutic targets for managing type 2 diabetes mellitus.